Category: Danaher Corp.
Danaher Corp. and private equity behemoth Blackstone are joining forces in the hunt for Johnson & Johnson's Ortho Clinical Diagnostics unit, anonymous sources tell Reuters.
Shares of Danaher Corp. rise after it beats Wall Street's earnings forecast and affirms its outlook for the rest of the year.
Danaher (NYSE:DHR) shares gained today after the conglomerate shattered Wall Street's 3rd-quarter earnings expectations and affirmed its outlook for the balance of 2013.
Johnson & Johnson puts its Ortho Clinical Diagnostics blood testing business on the auction block.
Share of Danaher Corp. are down today after the company reports 2nd-quarter results and narrows its earnings forecast for the rest of the year.
Danaher (NYSE:DHR) shares are down today on a narrowed earnings outlook for the rest of the year, after the conglomerate reported modest 2nd-quarter sales and earnings growth.
Danaher posts adjusted per-share earnings just a penny shy of Wall Street's consensus estimate, and the company's shares lose 2.5%.
Washington-based Danaher (NYSE:DHR) posted gains in its 1st-quarter 2013 sales and profits, but fell a penny short of analysts' earning expectations for the 3 months ended March 29, 2013.
Danaher sees healthy sales growth across all business segments and beats analysts' expectations for the 4th quarter of 2012.
Science and technology company Danaher (NYSE:DHR) posted increases across the board in its latest financial report detailing operations during the 4th quarter and full year of 2012.
Shine Medical raises $11 million for its alternative, non-nuclear method of creating imaging agents.
Shine Medical closed an $11.4 million funding round for its method of generating a low-energy neutron source for medical imaging that uses a particle accelerator instead of a nuclear reactor.